In the Decision Memo #CAG-00431N
issued on September 27, 2013, CMS determined that the evidence is
sufficient to conclude that for Medicare beneficiaries receiving
beta amyloid positron emission tomography (PET) in dementia and
neurodegenerative disease is reasonable and necessary only when the
provider is participating in and patients are enrolled in a
systematic data collection project. CMS will consider prospective
data collection systems to be qualified if they provide assurance
that specific hypotheses are addressed and they collect appropriate
data elements. The data collection should include baseline patient
characteristics; indications for the PET scan; PET scan results;
results of all other imaging studies; facility and provider
characteristics; dementia characteristics; disease management
changes; and treatment received.
US Code:
42
USC 1395Y Name of Law: Social Security Act
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.